Accès ouvert

Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa

Article scientifique 2020 Anglais

Résumé

Background: Neuroendocrine tumours are known to impact patients’ quality of life because of the symptoms caused by hypersecretion of serotonin and other peptides, in particular diarrhoea and flushing.Aim: The Q-SYMTU study was a prospective, observational registry that included 24 symptomatic patients with gastroenteropancreatic neuroendocrine tumours.Setting: Multiple oncology practices in South Africa.Method: Patients’ level of satisfaction was evaluated for a 6-month period from initiation of treatment with lanreotide Autogel.Results: The number of patients who had greater than 50% self-reported reduction in daily episodes of diarrhoea and flushing were 67% and 80%, respectively, over a 6-month period.Conclusion: Treatment with lanreotide Autogel was generally well tolerated, as demonstrated by low occurrence of Grade 3 and Grade 4 adverse events (AEs). None of the Grade 4 AEs were related to the study treatment. No Grade 5 AEs were reported.

Citer ce document

Geldenhuys, D., Rapoport, B., Fourie, S., Szpak, W., Rodrigues, S., Pirjol, A., Harris, J., Botha, M., Jonas, N., Nel, M., Bouharati, C., McMaster, A. (2020). Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa. https://doi.org/10.4102/sajo.v4i0.138

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Daleen Geldenhuys Bernardo L. Rapoport Samuel Fourie Waldemar Szpak Sylvia Rodrigues Anca I. Pirjol Jill Harris Michael C Botha Natalie Jonas Monique Nel Célia Bouharati Alicia McMaster

Statistiques

Consultations : 1

Téléchargements : 0